Related Experiment Video
Updated: Oct 29, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Matrix metalloprotease-14 is a target enzyme for detecting peritoneal metastasis in gastric cancer
Soichiro Ogawa1, Hidemasa Kubo1, Yasutoshi Murayama1
1Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
Background:
Accurate diagnosis of peritoneal metastasis in gastric cancer (GC) is important to determine the appropriate treatment. This study aimed to examine whether matrix metalloprotease-14 (MMP-14) was a candidate enzyme in fluorescence imaging for the diagnosis of peritoneal metastasis in GC.
Methods:
GC and normal peritoneal (NP) tissues from 96 and 20 patients, respectively were evaluated for MMP-14 expression. Live cell imaging of GC cell lines (NUGC4, MKN45, MKN74, HGC-27, and Kato-III) was performed using the MMP-14-activatable fluorescence probe; BODIPY-MMP. Furthermore, the overall survival (OS) was calculated in all patients (n = 96).
Results:
MMP-14 expression was significantly higher in GC tissues (median: 3.57 ng/mg protein; range:0.64-24.4 ng/mg protein) than in NP tissues (median: 1.34 ng/mg protein; median: 0.53-3.09 ng/mg protein) (P < 0.01). Receiver operating characteristic curves showed that the area under the curve, sensitivity, and specificity were 0.907, 84.4%, and 90.0%, respectively. In live cell imaging using the BODIPY-MMP, fluorescence was observed in five GC cell lines. In the analysis of OS, the high expression of the MMP-14 group had a significantly poorer OS rate than the low expression of the MMP-14 group (P = 0.02). In the multivariate analyses, MMP-14 expression was an independent risk factor for OS (hazard ratio: 2.33; 95 % confidence interval: 1.05-5.45; P = 0.04).
Conclusion:
MMP-14 is a promising enzyme in intraoperative fluorescence imaging for peritoneal metastasis in GC, especially in patients with poor prognosis.
Insights
Matrix metalloprotease-14 (MMP-14) shows higher expression in gastric cancer (GC) tissues, aiding in diagnosing peritoneal metastasis. Elevated MMP-14 levels also correlate with poorer overall survival in GC patients.
Area of Science:
- Oncology
- Surgical Oncology
- Diagnostic Imaging
Background:
- Accurate diagnosis of peritoneal metastasis is crucial for gastric cancer (GC) treatment planning.
- Matrix metalloprotease-14 (MMP-14) is investigated as a potential biomarker for peritoneal metastasis in GC.
Purpose of the Study:
- To evaluate MMP-14 as a candidate enzyme for fluorescence imaging in diagnosing peritoneal metastasis in GC.
- To assess the correlation between MMP-14 expression and overall survival in GC patients.
Main Methods:
- MMP-14 expression was quantified in GC and normal peritoneal tissues from 96 and 20 patients, respectively.
- Live cell imaging using an MMP-14-activatable probe (BODIPY-MMP) was performed on GC cell lines.
- Overall survival (OS) analysis was conducted for all 96 patients.
Main Results:
- MMP-14 expression was significantly higher in GC tissues compared to normal peritoneal tissues (P < 0.01).
- The MMP-14-activatable probe demonstrated fluorescence in GC cell lines, indicating diagnostic potential.
- High MMP-14 expression was associated with significantly poorer OS and identified as an independent risk factor for survival (P = 0.04).
Conclusions:
- MMP-14 is a promising enzyme for intraoperative fluorescence imaging of peritoneal metastasis in GC.
- MMP-14 may serve as a prognostic biomarker, particularly in patients with a poor prognosis.
